The FDA on March 6, 2024, approved OPDIVO® in combination with Cisplatin and Gemcitabine for first-line treatment of adult patients with unresectable or metastatic Urothelial Carcinoma (UC). OPDIVO® is a product of Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
